Clinical characteristics of restless legs syndrome in end‐stage renal failure and idiopathic RLS patients
Identifieur interne : 002940 ( Main/Exploration ); précédent : 002939; suivant : 002941Clinical characteristics of restless legs syndrome in end‐stage renal failure and idiopathic RLS patients
Auteurs : Minori Enomoto [Japon] ; Yuichi Inoue [Japon] ; Kazuyoshi Namba [Japon] ; Takashi Munezawa [Japon] ; Masato Matsuura [Japon]Source :
- Movement Disorders [ 0885-3185 ] ; 2008-04-30.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Adult, Age of Onset, Aged, Anticonvulsants (therapeutic use), Azepines (therapeutic use), Chronic renal failure, Clonazepam (therapeutic use), Dopamine Agents (therapeutic use), Female, Human, Humans, Idiopathic, Immobilization test, Kidney Failure, Chronic (complications), Kidney Failure, Chronic (therapy), Male, Middle Aged, Nervous system diseases, Peritoneal Dialysis, Polysomnography, Renal Dialysis, Renal failure, Restless Legs Syndrome (drug therapy), Restless Legs Syndrome (etiology), Restless Legs Syndrome (physiopathology), Restless legs syndrome, Terminal stage, Treatment, Treatment Outcome, Uremia (complications), Uremia (therapy), end stage renal disease, restless legs syndrome, severity, suggested immobilization test, treatment response.
- MESH :
- chemical , therapeutic use : Anticonvulsants, Azepines, Clonazepam, Dopamine Agents.
- complications : Kidney Failure, Chronic, Uremia.
- drug therapy : Restless Legs Syndrome.
- etiology : Restless Legs Syndrome.
- physiopathology : Restless Legs Syndrome.
- therapy : Kidney Failure, Chronic, Uremia.
- Adult, Age of Onset, Aged, Female, Humans, Male, Middle Aged, Peritoneal Dialysis, Polysomnography, Renal Dialysis, Treatment Outcome.
Abstract
This study was done to identify the clinical characteristics of uremic restless legs syndrome (RLS). Consecutive uremic RLS patients (n = 15) and idiopathic RLS patients (iRLS; n = 20) were evaluated. The groups were compared with respect to their clinical course, subjective symptoms [using the Pittsburgh Sleep Quality Index (PSQI) and the International Restless Legs Syndrome Severity Scale (IRLS)], polysomnographic (PSG) variables, the results of the suggested immobilization test (SIT), and the drug doses used to treat RLS. The duration of the disorder was significantly shorter in the uremic RLS group than in the iRLS group. The PSQI and IRLS scores before treatment were higher in the uremic RLS group than in the iRLS group. The periodic leg movement index (PLM index) on PSG and the SIT index were also higher in the uremic RLS group (P < 0.001, respectively). The bromocriptine equivalent dose of dopaminergic agonists used to treat RLS was significantly higher in the uremic RLS group (P < 0.001). Uremic RLS appears to deteriorate faster and to become more severe than iRLS. Moreover, uremic RLS patients appear to have a decreased response to dopaminergic agonists. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21882
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001787
- to stream Istex, to step Curation: 001787
- to stream Istex, to step Checkpoint: 001497
- to stream PubMed, to step Corpus: 002389
- to stream PubMed, to step Curation: 002389
- to stream PubMed, to step Checkpoint: 002380
- to stream Ncbi, to step Merge: 001F70
- to stream Ncbi, to step Curation: 001F70
- to stream Ncbi, to step Checkpoint: 001F70
- to stream Main, to step Merge: 003519
- to stream PascalFrancis, to step Corpus: 001272
- to stream PascalFrancis, to step Curation: 001A47
- to stream PascalFrancis, to step Checkpoint: 001325
- to stream Main, to step Merge: 003933
- to stream Main, to step Curation: 002940
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinical characteristics of restless legs syndrome in end‐stage renal failure and idiopathic RLS patients</title><author><name sortKey="Enomoto, Minori" sort="Enomoto, Minori" uniqKey="Enomoto M" first="Minori" last="Enomoto">Minori Enomoto</name></author><author><name sortKey="Inoue, Yuichi" sort="Inoue, Yuichi" uniqKey="Inoue Y" first="Yuichi" last="Inoue">Yuichi Inoue</name></author><author><name sortKey="Namba, Kazuyoshi" sort="Namba, Kazuyoshi" uniqKey="Namba K" first="Kazuyoshi" last="Namba">Kazuyoshi Namba</name></author><author><name sortKey="Munezawa, Takashi" sort="Munezawa, Takashi" uniqKey="Munezawa T" first="Takashi" last="Munezawa">Takashi Munezawa</name></author><author><name sortKey="Matsuura, Masato" sort="Matsuura, Masato" uniqKey="Matsuura M" first="Masato" last="Matsuura">Masato Matsuura</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D97604E6C9E1EE148A29CE482B490FFDDDE8DFB1</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1002/mds.21882</idno><idno type="url">https://api.istex.fr/document/D97604E6C9E1EE148A29CE482B490FFDDDE8DFB1/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001787</idno><idno type="wicri:Area/Istex/Curation">001787</idno><idno type="wicri:Area/Istex/Checkpoint">001497</idno><idno type="wicri:doubleKey">0885-3185:2008:Enomoto M:clinical:characteristics:of</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:18074382</idno><idno type="wicri:Area/PubMed/Corpus">002389</idno><idno type="wicri:Area/PubMed/Curation">002389</idno><idno type="wicri:Area/PubMed/Checkpoint">002380</idno><idno type="wicri:Area/Ncbi/Merge">001F70</idno><idno type="wicri:Area/Ncbi/Curation">001F70</idno><idno type="wicri:Area/Ncbi/Checkpoint">001F70</idno><idno type="wicri:Area/Main/Merge">003519</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:08-0251855</idno><idno type="wicri:Area/PascalFrancis/Corpus">001272</idno><idno type="wicri:Area/PascalFrancis/Curation">001A47</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001325</idno><idno type="wicri:doubleKey">0885-3185:2008:Enomoto M:clinical:characteristics:of</idno><idno type="wicri:Area/Main/Merge">003933</idno><idno type="wicri:Area/Main/Curation">002940</idno><idno type="wicri:Area/Main/Exploration">002940</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Clinical characteristics of restless legs syndrome in end‐stage renal failure and idiopathic RLS patients</title><author><name sortKey="Enomoto, Minori" sort="Enomoto, Minori" uniqKey="Enomoto M" first="Minori" last="Enomoto">Minori Enomoto</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Japan Somnology center, Neuropsychiatric Research Institute, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Psychophysiology, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Life Sciences and Bio‐informatics, Graduate School of Allied Health Sciences, Tokyo Medical and Dental University, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author><author><name sortKey="Inoue, Yuichi" sort="Inoue, Yuichi" uniqKey="Inoue Y" first="Yuichi" last="Inoue">Yuichi Inoue</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Japan Somnology center, Neuropsychiatric Research Institute, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author><author><name sortKey="Namba, Kazuyoshi" sort="Namba, Kazuyoshi" uniqKey="Namba K" first="Kazuyoshi" last="Namba">Kazuyoshi Namba</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Japan Somnology center, Neuropsychiatric Research Institute, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author><author><name sortKey="Munezawa, Takashi" sort="Munezawa, Takashi" uniqKey="Munezawa T" first="Takashi" last="Munezawa">Takashi Munezawa</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Japan Somnology center, Neuropsychiatric Research Institute, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author><author><name sortKey="Matsuura, Masato" sort="Matsuura, Masato" uniqKey="Matsuura M" first="Masato" last="Matsuura">Masato Matsuura</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Life Sciences and Bio‐informatics, Graduate School of Allied Health Sciences, Tokyo Medical and Dental University, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-04-30">2008-04-30</date><biblScope unit="vol">23</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="811">811</biblScope><biblScope unit="page" to="816">816</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">D97604E6C9E1EE148A29CE482B490FFDDDE8DFB1</idno><idno type="DOI">10.1002/mds.21882</idno><idno type="ArticleID">MDS21882</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Age of Onset</term><term>Aged</term><term>Anticonvulsants (therapeutic use)</term><term>Azepines (therapeutic use)</term><term>Chronic renal failure</term><term>Clonazepam (therapeutic use)</term><term>Dopamine Agents (therapeutic use)</term><term>Female</term><term>Human</term><term>Humans</term><term>Idiopathic</term><term>Immobilization test</term><term>Kidney Failure, Chronic (complications)</term><term>Kidney Failure, Chronic (therapy)</term><term>Male</term><term>Middle Aged</term><term>Nervous system diseases</term><term>Peritoneal Dialysis</term><term>Polysomnography</term><term>Renal Dialysis</term><term>Renal failure</term><term>Restless Legs Syndrome (drug therapy)</term><term>Restless Legs Syndrome (etiology)</term><term>Restless Legs Syndrome (physiopathology)</term><term>Restless legs syndrome</term><term>Terminal stage</term><term>Treatment</term><term>Treatment Outcome</term><term>Uremia (complications)</term><term>Uremia (therapy)</term><term>end stage renal disease</term><term>restless legs syndrome</term><term>severity</term><term>suggested immobilization test</term><term>treatment response</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anticonvulsants</term><term>Azepines</term><term>Clonazepam</term><term>Dopamine Agents</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Kidney Failure, Chronic</term><term>Uremia</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Restless Legs Syndrome</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Restless Legs Syndrome</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Restless Legs Syndrome</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Kidney Failure, Chronic</term><term>Uremia</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Age of Onset</term><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Peritoneal Dialysis</term><term>Polysomnography</term><term>Renal Dialysis</term><term>Treatment Outcome</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Homme</term><term>Idiopathique</term><term>Insuffisance rénale</term><term>Insuffisance rénale chronique</term><term>Pathologie du système nerveux</term><term>Stade terminal</term><term>Syndrome des jambes sans repos</term><term>Test immobilisation</term><term>Traitement</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This study was done to identify the clinical characteristics of uremic restless legs syndrome (RLS). Consecutive uremic RLS patients (n = 15) and idiopathic RLS patients (iRLS; n = 20) were evaluated. The groups were compared with respect to their clinical course, subjective symptoms [using the Pittsburgh Sleep Quality Index (PSQI) and the International Restless Legs Syndrome Severity Scale (IRLS)], polysomnographic (PSG) variables, the results of the suggested immobilization test (SIT), and the drug doses used to treat RLS. The duration of the disorder was significantly shorter in the uremic RLS group than in the iRLS group. The PSQI and IRLS scores before treatment were higher in the uremic RLS group than in the iRLS group. The periodic leg movement index (PLM index) on PSG and the SIT index were also higher in the uremic RLS group (P < 0.001, respectively). The bromocriptine equivalent dose of dopaminergic agonists used to treat RLS was significantly higher in the uremic RLS group (P < 0.001). Uremic RLS appears to deteriorate faster and to become more severe than iRLS. Moreover, uremic RLS patients appear to have a decreased response to dopaminergic agonists. © 2007 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Japon</li></country><settlement><li>Tokyo</li></settlement></list><tree><country name="Japon"><noRegion><name sortKey="Enomoto, Minori" sort="Enomoto, Minori" uniqKey="Enomoto M" first="Minori" last="Enomoto">Minori Enomoto</name></noRegion><name sortKey="Enomoto, Minori" sort="Enomoto, Minori" uniqKey="Enomoto M" first="Minori" last="Enomoto">Minori Enomoto</name><name sortKey="Enomoto, Minori" sort="Enomoto, Minori" uniqKey="Enomoto M" first="Minori" last="Enomoto">Minori Enomoto</name><name sortKey="Inoue, Yuichi" sort="Inoue, Yuichi" uniqKey="Inoue Y" first="Yuichi" last="Inoue">Yuichi Inoue</name><name sortKey="Matsuura, Masato" sort="Matsuura, Masato" uniqKey="Matsuura M" first="Masato" last="Matsuura">Masato Matsuura</name><name sortKey="Munezawa, Takashi" sort="Munezawa, Takashi" uniqKey="Munezawa T" first="Takashi" last="Munezawa">Takashi Munezawa</name><name sortKey="Namba, Kazuyoshi" sort="Namba, Kazuyoshi" uniqKey="Namba K" first="Kazuyoshi" last="Namba">Kazuyoshi Namba</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002940 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002940 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:D97604E6C9E1EE148A29CE482B490FFDDDE8DFB1
|texte= Clinical characteristics of restless legs syndrome in end‐stage renal failure and idiopathic RLS patients
}}
| This area was generated with Dilib version V0.6.23. |  |